Results 31 to 40 of about 852 (150)

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Journal of Nanobiotechnology, 2022
Background Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease mainly on account of hypercholesterolemia and may progress to cirrhosis and hepatocellular carcinoma.
Xiaozhi Hu, Jiajun Fan, Qianqian Ma, Lei Han, Zhonglian Cao, Caili Xu, Jingyun Luan, Guangjun Jing, Yanyang Nan, Tao Wu, Yuting Zhang, Hanqi Wang, Yuanzhen Zhang, Dianwen Ju   +13 more
doaj   +1 more source

New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review

Pharmaceuticals, 2022
Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality in developed countries.
Iveta Merćep, Dominik Strikić, Ana Marija Slišković, Željko Reiner   +3 more
doaj   +1 more source

Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans

Journal of Internal Medicine, Volume 300, Issue 3, Page 312-328, September 2026.
Abstract Background Angiopoietin‐like protein 3 (ANGPTL3) is a key circulating regulator of triglyceride metabolism and a promising pharmacological target. The physiological consequences of profound ANGPTL3 deficiency can be explored in individuals with inherited loss‐of‐function (LOF) variants, who show reduced lifetime risk of atherosclerotic ...
Marcello Arca, Elias Björnson, Laura D'Erasmo, Alessia Di Costanzo, Simone Bini, Ilenia Minicocci, Daniele Tramontano, Stella Covino, Giuseppe Ciarlo, Manuela Lombardi, Sanni Söderlund, Niina Matikainen, Linda Andersson, Martin Adiels, Marja‐Riitta Taskinen, Chris J. Packard, Jan Borén   +16 more
wiley   +1 more source

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia

Clinical Pharmacology: Advances and Applications, 2022
Constantine E Kosmas,1,2 Maria D Bousvarou,3 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,2 Rogers Echavarria Uceta,2 Eliscer Guzman1,2 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA ...
Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E   +6 more
doaj  

Antibodies to watch in 2022

mAbs, 2022
In this 13th annual installment of the annual ‘Antibodies to Watch’ article series, we discuss key events in commercial antibody therapeutics development that occurred in 2021 and forecast events that might occur in 2022.
Hélène Kaplon, Alicia Chenoweth, Silvia Crescioli, Janice M. Reichert   +3 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

LONG-TERM EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM SUBGROUP ANALYSES

American Journal of Preventive Cardiology
Therapeutic Area: Pharmacologic Therapy Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of early-onset ...
Daniel Gaudet, MD, PhD
doaj   +1 more source

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy

Frontiers in Genetics, 2022
Refractory hypercholesterolemia (RH), including homozygous familial hypercholesterolemia (HoFH) and compound heterozygous familial hypercholesterolemia, is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) despite existing ...
Zhi-Fan Li, Na-Qiong Wu
doaj   +1 more source

Olezarsen in Hypertriglyceridemia With High Cardiac Risk: A GRADE‐Assessed Meta‐Analysis of Randomized Trials With Trial Sequential Evidence

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This meta‐analysis of randomized trials evaluates olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. Olezarsen significantly improved triglycerides and other atherogenic lipid parameters with generally acceptable safety, supporting its potential as a promising adjunct therapy while highlighting the need for larger and longer ...
Ahmed Emara, Ameer Awashra, Heba Aboeldahab, Ahmed Farid Gadelmawla, Hamza A. Abdul‐Hafez, Abdullah M. Alharran, Amal A. Alsubaiei, Muneera Jasim AlRumaihi, Sara Ahmed Albuhmaid, Abdalhakim Shubietah   +9 more
wiley   +1 more source

Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study

Frontiers in Nutrition, 2023
BackgroundThe influences of blood lipids and lipid-regulatory medications on the risk of bladder cancer have long been suspected, and previous findings remain controversial.
Zhang Cheng, Zhang Cheng, Fangdie Ye, Fangdie Ye, Yingchun Liang, Yingchun Liang, Chenyang Xu, Chenyang Xu, Zheyu Zhang, Zheyu Zhang, Yuxi Ou, Yuxi Ou, Xinan Chen, Xinan Chen, Xiyu Dai, Xiyu Dai, Zezhong Mou, Zezhong Mou, Weijian Li, Weijian Li, Yiling Chen, Yiling Chen, Quan Zhou, Quan Zhou, Lujia Zou, Lujia Zou, Shanhua Mao, Shanhua Mao, Haowen Jiang, Haowen Jiang, Haowen Jiang   +30 more
doaj   +1 more source